Nivolumab (Opdivo®) for adjuvant treatment of oesophageal or gastro-oesophageal junction cancer. HTA ID: 21043

Assessment Status NCPE Assessment Process Complete
HTA ID 21043
Drug Nivolumab
Brand Opdivo®
Indication Nivolumab as monotherapy is indicated for the adjuvant treatment of adult patients with oesophageal or gastro-oesophageal junction cancer who have residual pathologic disease following prior neoadjuvant chemoradiotherapy.  
Assessment Process
Rapid review commissioned 21/09/2021
Rapid review completed 20/10/2021
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of nivolumab compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 28/10/2021
Pre-submission consultation with Applicant 20/12/2021
Full submission received from Applicant 11/05/2022
Preliminary review sent to Applicant 24/10/2022
NCPE assessment re-commenced 21/11/2022
Factual accuracy sent to Applicant 23/01/2023
NCPE assessment re-commenced 30/01/2023
NCPE assessment completed 13/02/2023
NCPE assessment outcome The NCPE recommends that nivolumab be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments*.

Technical Summary

Plain English Summary

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

The HSE has approved reimbursement following confidential price negotiations. September 2023